Please use this identifier to cite or link to this item:
http://hdl.handle.net/2445/152137
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Crippa, Jose Alexandre | - |
dc.contributor.author | Crippa, Ana C.S. | - |
dc.contributor.author | Hallak, Jaime E. C. | - |
dc.contributor.author | Martín-Santos Laffon, Rocío | - |
dc.contributor.author | Zuardi, Antonio W. | - |
dc.date.accessioned | 2020-03-05T17:59:02Z | - |
dc.date.available | 2020-03-05T17:59:02Z | - |
dc.date.issued | 2016-09-30 | - |
dc.identifier.issn | 1663-9812 | - |
dc.identifier.uri | http://hdl.handle.net/2445/152137 | - |
dc.description.abstract | Animal studies and preliminary clinical trials have shown that cannabidiol (CBD)-enriched extracts may have beneficial effects for children with treatment-resistant epilepsy. However, these compounds are not yet registered as medicines by regulatory agencies. We describe the cases of two children with treatment-resistant epilepsy (Case A with left frontal dysplasia and Case B with Dravet Syndrome) with initial symptom improvement after the introduction of CBD extracts followed by seizure worsening after a short time. The children presented typical signs of intoxication by Δ9-THC (inappropriate laughter, ataxia, reduced attention, and eye redness) after using a CBD-enriched extract. The extract was replaced by the same dose of purified CBD with no Δ9-THC in both cases, which led to improvement in intoxication signs and seizure remission. These cases support pre-clinical and preliminary clinical evidence suggesting that CBD may be effective for some patients with epilepsy. Moreover, the cases highlight the need for randomized clinical trials using high-quality and reliable substances to ascertain the safety and efficacy of cannabinoids as medicines. | - |
dc.format.extent | 6 p. | - |
dc.format.mimetype | application/pdf | - |
dc.language.iso | eng | - |
dc.publisher | Frontiers Media | - |
dc.relation.isformatof | Reproducció del document publicat a: https://doi.org/10.3389/fphar.2016.00359 | - |
dc.relation.ispartof | Frontiers in Pharmacology, 2016, vol. 7, p. 359 | - |
dc.relation.uri | https://doi.org/10.3389/fphar.2016.00359 | - |
dc.rights | cc-by (c) Crippa, Jose Alexandre et al., 2016 | - |
dc.rights.uri | http://creativecommons.org/licenses/by/3.0/es | - |
dc.source | Articles publicats en revistes (Medicina) | - |
dc.subject.classification | Cànnabis | - |
dc.subject.classification | Epilèpsia en els infants | - |
dc.subject.classification | Models animals en la investigació | - |
dc.subject.other | Cannabis | - |
dc.subject.other | Epilepsy in children | - |
dc.subject.other | Animal models in research | - |
dc.title | Δ9-THC Intoxication by Cannabidiol-Enriched Cannabis Extract in Two Children with Refractory Epilepsy: Full Remission after Switching to Purified Cannabidiol | - |
dc.type | info:eu-repo/semantics/article | - |
dc.type | info:eu-repo/semantics/publishedVersion | - |
dc.identifier.idgrec | 670030 | - |
dc.date.updated | 2020-03-05T17:59:02Z | - |
dc.rights.accessRights | info:eu-repo/semantics/openAccess | - |
dc.identifier.pmid | 27746737 | - |
Appears in Collections: | Articles publicats en revistes (Medicina) Articles publicats en revistes (Institut de Neurociències (UBNeuro)) Articles publicats en revistes (IDIBAPS: Institut d'investigacions Biomèdiques August Pi i Sunyer) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
670030.pdf | 1.2 MB | Adobe PDF | View/Open |
This item is licensed under a Creative Commons License